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UNSUSPECTED  BACTERIAL INFECTION IN DECEASED DONORS AND ITS 
IMPACT ON IMMEDIATE POST OPERATIVE INFECTIONS IN LIVER 
RECIPIENTS. 
 
INTRODUCTION :  
For end stage liver disease, liver transplantation is the best treatment.  The 
leading cause of morbidity and mortality in liver transplant patient is infection, 
especially bacterial infection in early post operative period.  Donors are one of the 
important source for bacterial infection. In past, It was considered systemic 
bacterial infection in donors as contraindication for organ donation for transmitting 
infection to immune suppressed recipient. It also affect transplanted liver‟s 
preservability and its function. Transplanted liver is less able to respond to the 
infective organisms because of recipient‟s immunosuppressive state. Their 
potential risks must be weighed against recipient‟s disease severity without 
transplant . 
At the same time, in the scenario of increasing demand for organs due to rise 
in liver diseases, every potential liver graft must be considered for transplant 
regardless of the infection, to minimize waiting list and mortality.
1
 
 Till now, unstable brain dead patients with severe bacterial and fungal 
sepsis(culture proved) is a contraindication for organ retrieval. 
18,59,64  
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Though some donors look clinically  stable, but still they may harbor 
bacterial infections.
 In most of the time, donor‟s  cultures results are  available only 
few days after transplant surgery   
10. 
 There must be every possibility of 
transmission of donor derived bacterial infection. This consequence of 
transmission of  unsuspected, donor infection to the recipients are not clearly 
known. Still controversies persists. 
 
 In recent studies, the infection related  complication in recipient due to 
infected graft are reported as less common and recommend for less restrictive 
policy of organ duration. But still the evidence are scarce and controversial 
11,53,78. 
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AIM: 
The aim of this study is to analyze the impact of  unsuspected donor 
bacterial infections in  recipients. 
OBJECTIVES: 
- To determine the incidence of bacterial donor infection. 
- To analyze duration of ICU stay and donor infections 
- To analyze donor risk factors for donor infection. 
- To analyze about recipient infection  in immediate post operative period 
(one week ).  
- To analyze about type of bacterial infections both in donors and recipients. 
- To analyze about the main risk factors and its impact on recipient infections. 
- To analyze the inﬂuence of donor infection on graft and patient short-term 
survival(30-day patient survival) 
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REVIEW OF LITERATURE: 
HISTORICAL REVIEW:  
Liver transplantation is a life saving procedure for end stage liver disease 
and acute fulminant liver failure.  
In 1963, Thomas Stazl performed first human liver transplantation at the 
university of Colaradu 
21
. But no one-year survival until over next 15 years. Only 
few liver transplantation were performed and achieved only 30% one year survival 
rate until late 1970s. One year survival was doubled in early 1980s due to 
introduction  of cyclosporine  based immunosuppressants.
3
 
In 1966,  Guy Alexandre from France brought about the concept of brain 
dead. Followed by the Harvard Ad Hoc Committee report   outlined  the  criteria  
for  brain  death  determination in 1968. After implementing these polices in 
clinical practice ,the  donor  pool  increased  significantly . 
Starzl and his colleagues first described about the technique of multiple-
organ procurement (kidney, liver, pancreas, small bowel) in 1984 In1992  
Nakazato and hi colleagues described  th new  technique  of total  abdominal  
evisceration  with  ex  vivo  dissection. 
5 
 
Since then, there was significant advancement in all aspect of liver 
transplantation including donor management, recipient selection, operation 
technique, immunosuppressants and post-operative care for recipient. 
The first successful Living Donor Liver Transplantation (LDLT) was done 
for a paediatric patient using lateral segments by Strong R.W in 1989. 
         Presently one year survival for Decreased Donor Liver Transplantion 
(DDLT) is more than 90% with 5 and 10 year survival in excess of 70% and 69% 
respectively 
34,35  
               
 
 
 
 
 
 
 
 
6 
 
TABLE 1. INDICATIONS FOR LIVER TRANSPLANTATION 
 
 Acute liver failure 
 
 Complications of cirrhosis  
 
 Ascites 
 
 Chronic gastrointestinal blood loss due to portal hypertensive gastropathy 
 
 Encephalopathy 
 
 Liver cancer 
 
 Refractory variceal hemorrhage 
 
 Synthetic dysfunction 
 
 
 Liver-based metabolic conditions with systemic manifestations  
 
 α1-Antitrypsin deficiency 
 
 Familial amyloidosis 
 
 Glycogen storage disease 
 
 Primary oxaluria 
 
 Tyrosemia 
 
 Urea cycle enzyme deficiencies 
 
 Wilson disease 
 
 
 Systemic complications of chronic liver disease  
 
 Hepatopulmonary syndrome 
 
 Portopulmonary hypertension 
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TABLE 2. ABSOLUTE CONTRAINDICATIONS TO LIVER 
TRANSPLANTATION 
 
 
 Acquired immunodeficiency syndrome 
 
 Active alcoholism or substance abuse 
 
 Advanced cardiac or pulmonary disease 
 
 Anatomic abnormality that precludes liver transplantation 
 
 Child-Turcotte-Pugh score <7 
 
 Cholangiocarcinoma 
 
 Extrahepatic malignancy 
 
 Fulminant hepatic failure with sustained ICP >50 mm Hg or CPP 
<40 mm Hg 
 
 Hemangiosarcoma 
 
 Persistent noncompliance 
 
 Uncontrolled sepsis 
 
 ICP, intracranial pressure; CPP, cerebral perfusion pressure; CPP, equals the 
mean arterial pressure minus ICP. 
  
DONOR MANAGEMENT:  
    Brain death is defined as the irreversible loss of all function of the brain 
including the brain stem. Coma, absence of brain stem reflexes and apnea are 
essential findings in brain death. 
 Evaluation for brain death should be considered in patients with a massive 
irreversible injury of identifiable cause. A patient who is declared as brain dead is 
legally and clinically dead. 
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TABLE  3. Physiological derangements seen in brain-dead donors
85
 : 
Derangement Cause 
Hypothermia Hypothalamic damage,reduced metabolic rate, vasodilation 
and heat loss. 
Hypotension Vasoplegia, hypovolaemia, reduced coronary blood ﬂow; 
myocardial 
Dysfunction. 
Diabetes insipidus Posterior pituitary damage. 
Disseminated intravascular 
coagulation 
Tissue factor release; coagulopathy. 
Arrhythmias „Catecholamine storm‟, myocardial damage, reduced 
coronary blood ﬂow. 
Pulmonary oedema Acute blood volume diversion,capillary damage. 
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PRINCIPLES OF DONOR MANAGEMENT 
66
 : 
General care: 
            Patients are managed in ICU(Intensive care unit). Minimum invasive 
cardiovascular monitoring includes arterial and central venous pressure. Cardiac 
output monitoring preferred. Unnecessary drugs should be Stopped, e.g. sedatives. 
Reduce heat loss and actively warm if necessary to maintain core temperature 
˃35C. Current infections should be actively identified and treated. May require 
bronchoalveolar lavage. 
Respiratory system: 
  Tidal volume should be 6–8 ml kg with optimal PEEP(Positive end 
expiratory pressure) to allow minimum FIo2.. Maintain tracheal cuff pressure 
should be maintained at 25 cm H 2 O and nurse with the head of the bed elevated 
to reduce the risk of aspiration. the administration of excessive ﬂuids should be 
avoided. Diuretics should be considered if marked ﬂuid overload is suspected. 
Cardiovascular system: 
Fluid balance should be reviewed periodically and hypovolaemia should be 
corrected. Cardiac output monitoring should be used to titrate ﬂuids and inotropic 
or pressor drugs to intended goals as guided by retrieval team. If vasopressor drugs 
10 
 
required, vasopressin 0–2.4 units/h  may reduce catecholamine requirements. High 
doses of catecholamines (e.g. norepinephrine .0.05µg/kg/ min ) should be avoided 
if possible. Consider triiodothyronine bolus and infusion. 
Fluids and nutrition: 
Positive balance and hypernatraemia should be avoided. Urine output should 
be maintain at 0.5–2.5 ml/kg/h . If urine output is .4 ml/ kg, consider diagnosis of 
diabetes insipidus and treat with vasopressin infusion or Desmopressin. Blood 
glucose target concentrations 4–8 mmol/litre. Electrolyte abnormalities should be 
corrected to normal values.  
Blood and coagulation: 
      Coagulation should be corrected if evidence of active bleeding;  coagulation 
support should be considered during retrieval. Consider need for transfusion may 
be considered. Thrombo prophylaxis considered maintained as there is a high 
incidence of pulmonary emboli found at retrieval. 
Systemic effects:  
       Methylprednisolone 15 mg/kg bolus should be administrated  immediately 
after brain death is  conﬁrmed and also triiodothyronine. 
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Infections: 
All should be  treated  with  proper  antibiotics  and urine, sputum , blood, 
other cultures if necessary other cultures should be obtained before starting 
antibiotics. 
Investigations: 
Routine ECG, echocardiogram should be done. Bronchoscopy and lavage 
followed by lung recruitment maneuvers should be done. Chest X-ray after lung 
recruitment maneuvers should be taken. 
 
RECIPIENT SELECTION:  
Deog-bog Moon et al
21 
sai that the presence of  cirrhosis alone is a not a 
sufficient indication for transplantation, since the well compensated cirrhotic 
patients can remain stable for long time.  
 Since 2002, the unite network for organ sharing applying model of end stage 
liver disease (MELD) scoring system for an organ allocation, cirrhotic patients has 
to meet minimal listing criteria for placement in waiting list 
47. 
 This score predicts 
the 3 months mortality of the waiting patient. This score is based on laboratory 
value : Serum creatinine, bilirubin and INR. 
12 
 
 
 MELD  score 84                                                  Three-month mortality(Hospitalized 
patients) 
≤9                                                                                           4% 
10-19                                                                                    27% 
20-29                                                                                   76% 
30-39                                                                                   83% 
≥40                                                                                      100% 
MELD  score=9.57×log e  (Creatinine  mg/dl)+3.78×log e  (Bilirubin  mg/dl)+11.20×log e  
(INR)+6.43 
 
In patient with MELD score more than 30,  3 month survival rate is less than 20%. 
MELD score of less than 15 can lead a near normal life  without liver transplant. 
MELD score more than 10 (Child-Turcotte-Pugh score ≥ 7) or any complication 
related to portal hypertension  or acute fulminnt liver failure are the indication for 
transplant evaluation 
52 . 
MELD score of less than 10 are ineligible for listing since 
they have better survival without transplant.   
IMMUNOSUPPRESSANT  TREATMENT: 
The basic regimen used in liver transplant  is combination of  tacrolimus and 
steroids. Target trough level of tacrolimus in first 2 weeks should be maintained as 
10-15ng/ml and 5-10ng/ml during first 2 months after liver transplant. 
TABLE. 4: MELD SCORE  
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Methylprednisolone (20mg/kg body weight) should be give during the anhepatic 
phase of surgery, then 2mg/kg for first 3 days.  It is tapered to 1 mg/kg for 3 days 
and converted to 1 mg/kg/day prednisolone.  Prednisolone is weaned gradually and 
discontinued after 6 months.  
INFECTION PATTERN AFTER LIVER TRASNPLANTATION: 
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Post transplantation recipient‟s infection are studied into three time 
periods 
86
. First period immediately starts after transplantation and extend 
to one month. Most of the infections are bacterial infection either related to 
donor or recipient like technical or surgical issues and complications. 
Bacterial and candidal wound infections, central catheter related infection , 
urinary tract infections and pneumonias are common in this period. 
Second period extends from second month to sixth months. During this 
period , opportunistic infections are dominating as result of immunesuppression. 
Cytomegalovirus,Aspergillus and pneumocystis jiroveci are commonly seen. 
The third period starts from seventh month to twelfth month and beyond. 
Reactivation of human herpes virus and  manifest as herpes zoster, and also  
cytomegalovirus  infections  can  occur. Apart from this, the pattern of infections 
are similar to the patients ,not underwent transplant surgery.   
BACTERIAL INFECTION IN LIVER TRANSPLANTAION 
CDC  DEFINITIONS  FOR  NOSOCOMIAL  INFECTIONS: 
33 
 
Bacteremia  is  considered  to  be  present  when  Staphylococcus  aureus,  
Candida  species,  or  Gram- negative  rods  are  isolated  from  at  least  1  blood  
culture.   The   other   pathogens   are   considered  positive  when  they  are  
isolated  from  2  blood  cultures  from  the  site  considered  as  the  infection  site.  
15 
 
Primary  bacteremia  is  defined  as  bacteremia with   no   physical,   
radiological,   or   pathological  evidence  of  a  definite  infection  source.  
Secondary bacteremia is deﬁned as bacteremia if the source of the 
bacteremia was identiﬁed [ie, an organism isolated  from  a  blood  culture  was  
compatible  with  a related  nosocomial  infection  at  another  infected  site(urine;  
intra-abdominal  abscess,  bile,  or  peritoneal ﬂuid; or bronchoalveolar ﬂuid or 
bronchial aspirate)]. 
        Catheter-related  bacteremia  is  defined  when  more  than 15  colony-
forming  units  of  bacteria  is cultured  from  the  catheter  tip,  irrespective  of  
whether  the  same   organism  is isolated   from   the   blood  culture. 
Bacteremia  caused  by  common  skin  contaminants is  considered  
signiﬁcant  only  if  the  organism  is isolated  from  2  blood  cultures  and  it  was  
accompanied by clinical signs of infection. 
Donor-derived disease transmissions are deﬁned as any disease present in 
the organ donor that is transmitted to at least one of the recipients. 
BACTERIAL INFECTION IN BRAIN DEAD: 
The diagnosis of infection is very difficult in brain injured patient only based 
on clinical suspicion. It is because that brain injured patients presents with 
16 
 
hyperthermia and hemodynamic instability as found in bacterial sepsis , attributed 
to brain damage rather than sepsis. Brain injury impair the cellular immune system 
and also cause hemodynamic instability. This will predispose to infection due to 
bacterial translocation from gut 
46,71. 
IDEAL DONOR : 
 The ideal donor should have following features 
50
: 
1. Age 50 years or less 
2. Donors without hepato biliary disease 
3. Hemodynamically stable donor(systolic blood pressure ≥100 mmHg and 
central venous pressure more than 5cm of water) 
4. Donor with respiratory stability 
5. Donor without severe abdominal trauma, systemic infection and 
cancer(with few exceptions). 
6. Diuresis >50ml/hr with normal serum creatinine 
7. Dopamine requirement < 10µg/kg body weight/min 
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SUBOPTIMAL DONORS : 
In past, donor with severe bacterial sepsis are considered as absolute 
contraindication for organ donation
17
 . Recently many reports have documented 
only isolated incidents of infection transmission from donor to recipient 
29,57,72
. But 
when it is transmitted to recipients , it is associated with significant morbidities. 
This may result in hepatic artery anastomotic disruption, poor graph function, 
sepsis and death 
7,15,60,24,25,27,57,72
. Especially, when there is combined bacterial and 
fungal infection in donor 
1 ,10
.  
But considering  critical shortage of organ and  waiting list mortality ,these 
infected suboptimal organs are now accepted for organ donation 
22
.  
At present, donor with abnormal liver function test, prolonged ICU stay, 
hemodynamic instability, age > 65 years and steatic liver are not considered as 
contraindication for organ donation 
23,36,50
. 
DONOR INFECTION IN ICU : 
 Donor stay in ICU increases the risk of nosocomal infection and account for 
33% to 45% of all nosocomal bacteremias 
6,67. 
 The common infections are vascular 
access infection, bladder catheter-related infection and ventilator associated 
pneumonia 
14. 
18 
 
The European prevalence of infection in intensive care study (EPIC) have 
reported that 45% of ICU patients had atleast one or more infections 
70. 
 
 Coma is associated with high risk of nosocomial pneumonia especially if 
they are with ventilator support 
13,26,68. 
 
Approximately 3-8% of patients with urinary catheter develop urinary tract 
infection and its related secondary bacteremia 
48,54.
 
 Cerrutti et al 
11
 reported 48% of donors had atleast one culture is positive for 
bacterial growth. These infected donors were either older age or had longer ICU 
stay (>=3 days). In spite of that , only 3.7% of donor infection transmission to 
recipient occurred without affecting  one year survival of the graft.  Similarly 
Gonazales – Segura  et al reported prolonged ICU stay resulted in more donor 
infection incidence 
35
.  
 Another study stated as the risk factors of donor infection are prolonged ICU 
stay, mechanical ventilation, invasive procedure and devices, inadequate nursing 
and medical management 
1,9,63
.  
DONOR ORGAN CONTAMINATION: 
Bacterial contamination of organs in the donor occurs frequently but rarely 
infection is transmitted to recipients. 
10
  organ perfusion fluid Cultures   may be  
19 
 
positive  in  up  to 40% .  Most  of them are  with  non virulent  skin  flora and  
correlated  poorly  with  the  occurrence  of  post transplant  allograft  infection. 
22
 
Gottesdiener KMet al 
37  
reported that these  bacterial- fungal contaminations 
occur during harvesting and in preservation ﬂuid  . It can occur with many 
common aerobic bacteria. And also said that fungi, yeast and toxoplasmosis are 
transmitted less frequently.  
But in another study by Zibari GB et al  warned about the contamination of 
organs during process of harvesting  he reported as they may lead to severe 
infection in the recipient, especially if contaminants are by more virulent 
organisms.
79
 
EVIDENCE OF DONOR DERIVED BACTERIAL INFECTION IN RECIPIENT : 
 To confirm the donor transmitted bacterial infection in recipient, it is 
important to identify the type of microorganism causes infection in both donor and 
recipient.  Identifying the bacterial genome is the only way to confirm the 
transmission of infection from donor to recipient. Unfortunately the bacterial 
genome typing is not widely available and not feasible in practice. So practically, 
the evidence of information transmission is confirmed by identifying the same 
organisms with same antibiotic susceptibility pattern identified  between the donor 
and the recipient 
1
. 
20 
 
INCIDENCE OF THE BACTERIAL TRANSMISSION : 
 The incidence of donor derived bacterial infection in recipient varies 
between 1-8% 
1,10,35,79
.  The incidence of unsuspected donor derived infection in 
recipient is less than 1%. The donor should always be considered as the source of 
infection for all early post transplant bacterial infection in recipient. Since, 
currently no standardized bio vigilance system is available to recognize the 
transmission 
43
.  
Donor  culture  positivity  do not influence the global recipient and 
graft survival rates. The explanation is that the transmission rate was kept 
low by careful microbiologic  surveillance  of  the  graft   and prompt 
institution of the speciﬁc antimicrobial therapy against any pathogen 
microorganism isolated  in  the  donor.
 62
 
 THE RISK FACTORS TO SUSPECT DONOR INFECTION: 
 Wu JJ et al did a study in DDLT patients and found that ICU stay 
≥7 days, inotrope supports and cardiac arrest are independent factors to 
predict donor infection. But these infections did not affect the one year 
survival of the recipient 
74
. 
 In another study, it was reported as combined bacteremia and sepsis in donor 
is associated with higher incidence of infection transmission to recipient and 
21 
 
infection related morbidity
17
. Still, donor infection with low virulence organism 
with adequate antibiotic treatment allow safer organ donation 
25,32,79
. 
 Length of ICU stay ≥2 days, mechanical ventilation, trauma, invasive 
devices, interventional procedures, adverse background and stress ulcer 
prophylaxis are considered as important risk factors for donor information 
2,70
. 
RECIPIENT INFECTIONS :   
 Most of the bacterial infection occurred in first month after transplantation 
with incidence of bacteremia ranging form 21% to 33% 
38,49
. In which donor 
related bacterial infections manifest within 3 to 12 days 
46,71
. Hence, for any early 
post operative bacterial infection, it is always better to consider the potentiality of 
donor origin.  
RISK FACTORS FOR RECIPIENTS : 
The intensity of exposure to pathogens and overall immune suppression 
level are the main risk factors determining the chance of infection transmission to 
the recipients. Regarding immunosuppressants , the dose, duration of treatment, 
choice of the immunosuppressant are important factors which influence “the net 
safe of immune suppression level”.  
22 
 
 Similarly other factors must be considered are underlying immune 
deficiencies state ,the presence of lymphopenia, neutropenia, the presence of 
necrotic tissue, intra-abdominal fluid collection, intestinal mucosa integrity, poorly 
controlled diabetic mellitus and associated infection due to immune modulating 
viruses 
31
. 
          The patients with cirrhosis are vulnerable to bacterial infection and with risk 
of dying from uncontrolled sepsis. The recipients with cirrhosis are susceptible to 
infection due to immune dysfunction 
30
,especially if the recipient is  with higher 
MELD score 
40
. 
 Post operative management, duration of ICU stay, early removal of invasive 
device like central venous catheter, urinary catheter and short duration of hospital 
stay are important factors in reducing the rate of recipient infection. 
 One study has reported that uncontrolled diabetes mellitus, renal failure and 
hypoalbuminemia are independent predictors of bacterial infection in liver 
transplant recipients 
65
. 
 The patients vulnerability to infection are strongly influenced by surgical 
factors, environmental exposure, the state of immunesuppression and the type, 
dose and duration of prophylaxis 
80
. 
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 Hill et al reported that longer hospitalization before transplantation or in post 
operative period, the diabetic control , pretransplant renal failure and 
hypoalbuminemia are independently significant risk factors for recipients bacterial 
infection 
39
. 
 Losada et al stated administration of parenteral nutrition, duration of 
recipient surgery for more than 5 hours, organ rejection and pretransplant CMV 
status are the sole factors for early infection in liver transplant recipients. The 
incidence is higher for first thirty days, predominantly due to bacterial infection. 
Among all duration of recipient surgery, especially more than 5 hours is most 
important risk factor for acquiring bacterial infection. Selective bowel 
decontamination especially for gram negative organisms. 
          Paya CV et al 
59
 reported bacterial infections most commonly occurred in 
first two months after liver transplantation. In his series, the duration of the 
transplantation surgery especially more than 12 hours is the main risk factor for 
bacterial infection. 
 Hsin-yun sun et al 
41
 studied about bacterial infection related mortality in 
one hundred consecutive transplant recipients. He concluded that  the recipients 
with high MELD score is the important predicting factor for post transplant 
24 
 
infection.  The adequately treated pretransplant bacterial infection do not pose a 
significant risk for post transplant bacterial infections or related outcomes.  
 Similarly, the spectrum of bacterial organisms and its antibiotic sensitivity 
pattern are not influencing the post transplant infection rate . 
 The underlying disease severity, high intra operative blood loss, renal 
failure, subsequent dialysis strongly influence the morbidity and mortality of 
recipient due to post transplant bacterial infections.  
 Singh et al 
64
 stated that diabetes mellitus, CMV status and 
hypoalbuminemia are important risk factors for bacterial infections in recipient. 
 Wade JJ et al 
73
 reported acute rejection, longer hospitalization,  acute liver 
failure , elevated serum bilirubin level, prolonged operative time 
4
 are the risk 
factors for bacterial infections.  
BACTERIAL ORGANISMS : 
 The type of bacterial organisms commonly reported in donor and recipients 
infections widely varies between institutions.  
 Several centers have reported that gram – negative infection constitute about 
65% of bacterial infections 
38,49,76 
. 
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 Paya CV et al 
59
 reported that gram negative organisms are more commonly 
(60%) seen in recipient in early infection. 
 Losada et al 81 reported that 77.9% of bacterial infection are due to gram 
positive organisms in his study. 
 Bull DA et al  stated that gram negative bacterial infections pose a great risk 
of transmission and associated with poor outcome 
7
. 
 Virulence of pathogens remain as an important risk predictor of the outcome 
of the bacterial infection. Bacterial infection caused by acinetobacter baumanni, 
results in worst outcome and high mortality varying between 22-52%. 
 Another study reported as gram positive bacteria such as Staphylococcus 
aureus and Enterococcus are commonly found organisms in bacterial infection and 
also associated with high morbidity and mortality 
75
. 
 Regarding donor infections, the European Prevalance of infection in 
Intensive Care (EPIC) study 
70
. studied about the prevalence of nosocomial 
infection in ICU. They reported most commonly found organisms were 
Staphylococcus aureus (30.1%) which include MRSA- 60% and enterobacteriaceae 
(34.4%) followed by Pseudomonas aeruginosa(28.7%) Coagulase negative 
Staphylococci (19.1%) and importantly fungal infection (7.1%). 
26 
 
 Though the prevalence of type of bacterial organisms are varying between 
centers, the  virulence of organisms and associated fungal infection are associated 
with greater risk of transmission and following morbidity and mortality in 
recipient. 
ROLE OF ANTIBIOTICS IN DONORS : 
  The donor with proven bacterial sepsis must be treated with appropriate 
antibiotics at least for minimum period of 2 weeks by bactericidal therapy and 
followed by proof of cure before organ retrieval. 
 Similarly donor with only bacteremia considered for organ donation after 
receiving appropriate antibiotics for at least 48 hours prior to organ retrieval. 
  Regarding duration of antibiotics in recipients, no controlled trials are 
available indicating the optimal duration. These recipients should treated with 
antimicrobial prophylaxis for at least 48 hrs after transplantation. But most of 
transplant centers, continues culture specific antibiotics for 5-7 days
1
. 
 Regarding the eligibility of infected donor for organ donation. The Israel 
transplant guideline recommended that the organisms must be susceptible to 
antibiotic therapy, irrespective of the virulence of organisms. At least 48 hrs 
duration of antibiotic therapy prior to organ retrieval should be given. There must 
be evidence of clinical response to antibiotic treatment with decreasing fever total 
27 
 
white cell count and reducing requirement of inotropic support. Similarly the 
recipient with infected donor grafts should receive culture specific antibiotics for at 
least one week following transplantation. 
ROLE OF  ANTIBIOTIC IN RECIPIENT’S INFECTIONS : 
 Although no randomized controlled studies are not available, most of the 
transplant centers administer perioperative antibiotics prophylaxis for 24 -48 hrs 
following transplant surgery 
58
. The antibacterial regimen should be chose, based 
on targeting gastrointestinal flora and Staphylococcus aureus. 
 In recently infected recipient with known culture and sensitivity status, the 
antibiotic should be chose based on pretransplant  culture report till getting the 
recipients post transplant culture status 
58
. 
 Routine post transplant antibiotic in recipients definitely reduces the risk of 
transmission of bacterial infection from donors 
22
. 
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HOSPITAL STAY : 
 Infection related complications prolong the recipient hospital stay. These 
recipients are undergoing number of invasive procedures and interventions. This 
will increase associated  medical expenditures. It possess huge financial burden 
and man power utilization to both the patient and health system 
42
. 
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MATERIALS AND METHOD : 
Deceased donor liver transportation are done in our department since 2008. 
This is a prospective comparative study to find out risk factors for bacterial 
infection in donors and donor related recipient infections. The study was conducted 
from August  2009 to January 2012. The study period is thirty  months.   
Inclusion criteria:  
- The clinically stable donors whose culture status is not known before 
transplantation. 
- The recipients underwent deceased donor liver transplantation. 
Exclusion criteria : 
- Cadaver with overt sepsis 
- Ineligible cadaver for organ donation , due to other medical and ethical 
reasons.  
- Recipient with pre transplant culture positive status  
- Recipient who developed infection after one week. 
- Recipient who died in first week after transplantation due to non-infectious 
cause.    
30 
 
Donor data composed of age, sex , BMI, duration of intensive care unit  stay 
before organ harvesting,  associated injuries,  pre-harvesting intervention 
procedure, antibiotic therapy, blood and urine culture, organ preservative fluid 
culture,  duration of donor surgery.  Recipient data composed of age, sex, etiology, 
MELD score, indication for transplantation ,  pre and  post-operative infection 
status of recipient, duration of hospital stay and outcome. Data were collected 
prospectively. 
Infections found in recipient in first week of post operative period were 
considered as donor origin, provided no evidence of pre operative recipient 
infections and no organ contamination were ensured. Thirty days infection related 
morbidities and mortality were studied. 
Since genomic typing techniques were not applied at the time of microorganism 
isolation in the donor, deﬁnite evidence of infection transmission from donor to 
recipient could not be  acquired.  However,  for  the  purpose  of  the  study, 
Infection transmission was considered to have occurred when all of the following 
surrogate criteria were satisﬁed: 
 (1) identity of species between the microorganism isolated in the donor and the 
one isolated in the recipient,  
(2) identity of antibiotic susceptibility pattern of the isolated microorganisms,  
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(3) presence of clinical signs of infection in the recipient. 
DONOR: 
Liver was harvested from various institutions. Brain dead patient are 
managed in ICU with ventilator support by specially trained anesthetist team. 
Patient are resuscitated and maintained with supportive treatment .  
All precautions are taken to prevent donor sepsis .Hemodynamic stability 
was maintained with vasopressors to prevent hypo perfusion of vital organs. 
Culture from blood , urine , tracheal aspiration and external wound ( if present ) 
were routinely done periodically , one at the time of admission and another one just 
before donor surgery. 
Patients are routinely given prophylactic broad spectrum antibiotics after 
taking culture. Organ were not harvested from donor overt sepsis,  
hemodynamically unstable despite appropriate inotropic support and donors who 
sustained multiple cardiac arrest. 
Donor samples obtained in the ICU on the days or before organ recovery 
included blood, tracheal aspirate, urine and any other site of clinically suspected 
infection, as well as the preservation ﬂuids at organ recovery. Blood cultures in the 
donor may therefore frequently be unavailable at the time of harvesting of the 
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organs. Donor surgery is conducted by a well trained anesthetist and surgeons 
team.  
HTK solutions is used as organ perfusion fluid. Just before starting the 
surgery , carbapenam antibiotics, anti fungal will be given . Just before cross 
clamping the aorta , unfractioned heparin are given. Bench dissection is done in 
our operation theatre by donor team . All the vascular anomalies are noted . 
Appropriate reconstruction are done. Donor iliac vessels were used as vascular 
graft for hepatic artery reconstruction if needed. 
RECIPIENT: 
Recipient are selected on basis of MELD score. Preoperative cultures taken 
from blood , urine , throat swab along with basic blood investigations and organ 
specific investigations. Recipient surgery are started after ensuring the donor liver 
status. Intra operative culture are done if free fluid is found in abdomen.   
Explanted liver gross cut section are studied before sending it for 
histopathological  examination. Cadaveric liver is transplanted to recipient. First 
the recipient‟s IVC to donor hepatic vein anastomosis is done by “ PIGGY BAG “ 
technique. Then followed by portal vein , hepatic artery and at last bile duct 
anastomosis are done. New liver perfusion are confirmed by intra operative 
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ultrasound doppler examination. Recipients are managed in ICU in early post 
operative periods. 
Recipient data included the prophylaxis received and the type and etiology 
of infection. Samples from biological ﬂuids were cultured only in cases of 
clinically suspected infection. Periodical culture to recipient were done on clinical 
grounds.  
All bile samples and ascites or pleural ﬂuid samples were  obtained  from  a  
proper  drainage  tube  or  by puncture,  and  were  collected  in  a  sterile  
container. Gram-staining  and  conventional  culture  were  performed. 
Identiﬁcation  of  fungal  species  was  done  in  accordance  with  standard  
method. 
      we considered a true bacterial infection as an isolation of a microorganism 
from a sterile site or from another site in the presence of clinical symptoms or signs 
of infection. We did not consider true infection those febrile episodes without 
microorganism isolation and resolved without empirical antibiotic treatment. 
     When pathogens were isolated from donor cultures, the standard prophylactic 
regimen  was changed to speciﬁc antibiotic therapy against the donor‟s 
microorganism and infection; In non- survivors, the date and cause of death were 
recorded. Recipient data were collected up to 30 days following the procedure.  
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Patient received immunosuppressant – tacrolimus after  24 hrs . Dose will be 
adjusted according to periodical serum tacrolimus level assay.  Additionally, MMF 
are started after one week. Oral steroid dose gradually tapped and stopped in-  4-6 
months period. 
The  following  data  were  recorded:  organism,  antimicrobial  
susceptibility,  source  of  bacteremia,  temperature,  severity  of  sepsis,  treatment  
and outcome. Blood  cultures sample  at  harvest  were  always  drawn through 
femoral artery with particular attention to asepsis made. Samples from preservation 
ﬂuid were collected at the beginning of the back-table procedure that. 
Donors with 1 or more samples positive for bacteria or fungi were deﬁned 
“culture positive” (CP); the others were deﬁned “culture negative” (CN). Cultures 
were evaluated by a microbiologist  to  distinguish  pathogen  microorganisms 
from contaminants/possible pathogens. 
For the purposes of the study, donor-to-host transmission was established 
when a positive isolate from a donor matched any positive culture in the respective 
recipient during the ﬁrst 7 days after the procedure in the presence of clinical signs 
of infection and the same antibiotic susceptibility pattern.
82
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STATISTICAL ANALYSIS: 
 
The statistical analysis of this study was done by using the SPSS software 
version 15. Values were expressed as means ± standard deviations, and range as 
appropriate. Statistical analysis of qualitative variables were performed using the 
chi-square test, and quantitative variables were tested using the student t-test test. 
A difference was considered statistically significant when p vaue was < 0.05. 
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RESULTS : 
The study period was thirty months  from august 2009 to January 2012. 
Thirty three transplantation were done within the study period. They were all 
included in the study. Since all the donors and recipients met both inclusion and 
exclusion criteria. 
DONORS:  
BRAIN DEAD:  
During this study period, twelve  brain dead patients  with  severe sepsis 
with hemodynamic instability not harvested Thirty three donors,  who were 
clinically stable  underwent donor surgery. 73.3% of brain dead patients  were 
effectively utilized as ideal donors. 
CAUSE OF DEATH: 
Regarding  the donors ,Thirty two donors died due to road traffic accidents. 
One donor died due to subarachnoid hemorrhage due to cerebrovascular accident 
and underwent craniotomy. 
 ORGANS HARVESTED:  
Number of organs harvested were : Thirty six liver, seventy two kidneys , 
ten hearts and fifty corneas. 
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Seria
l no. 
Donor variables N Mean±SD(range)                                                     „p‟ value 
Univariat
e analysis  
Multivariate 
analysis 
pertaining to 
donor 
culture 
status 
Multivariate analysis  
pertaining to (Recipient factors) 
Same 
organis
ms 
Morbidit
y 
Mortalit
y 
1 Age  :  
More than 50 yrs 
Less than 50 yrs 
 
6 
27 
35.2±13.2(19- 
65) 
 
 
0.13 0.63 0.49 0.864 0.33 
2  Sex: 
Male  
female 
 
30 
3 
 
- 
0.12 0.39 0.13 0.16 0.25 
3.  BMI  
- 
25.25±1.5(21.6-
28.9) 
 
 0.49 0.32 0.80 0.73 
3 Alcoholic  13 - 0.822 0.72 0.15 0.96 0.66 
4 ICU stay: 
More than 2 
days 
Less than 2 days  
 
23 
10 
3.58± 1.9 ( 2- 9)  
 
 
0.231 0.86 0.24 0.44 0.38 
5 Diabetes 5 - 0.443 0.91 0.37 0.62 0.38 
6 Inotropic 
support 
- 1.61 ± 0 .704 (1 - 
3 ) 
0.001 0.001 0.05 0.006 0.24 
                 TABLE 5. THE BASELINE CHARACTERISTICS OF CADAVERIC LIVER DONORS 
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7 Total WBC 
count 
(per cumm) 
- 11862 ±  5711 
(2700 - 30000) 
0.001 0.001 0.75 0.36 0.47 
8 Platelets count 
(Per cu mm) 
- 96039±45828(12
300- 160000) 
0.04 0.33 1.0 0.033 0.002 
9 Total bilirubin 
(mgs/dl) 
- 1.05  ± 0.64(0 .4 
- 2.6 ) 
0.63 0.40 0.46 0.62 0.38 
10 ALT(U/dl) - 175±95.6 (42-
1400) 
0.01 0.01 0.45 0.06 0.22 
11 Blood 
urea(mgs/dl) 
- 47.91 ± 12.16 
(23.5  - 74.4) 
0.07 0.03 0.27 0.066 0.56 
12 Serum 
creatinine(mgs/d
l) 
- 3.2  ±0.3 (0.58- 
1.14 ) 
0.02 0.01 0.12 0.29 0.29 
13 Serum 
sodium(meq/L) 
- 147.03 ±  7.4 
(132.3 -164.3) 
1.00 0.81 0.10 0.25 0.85 
 
 
s.no Characteristic                                                        Donor status „P‟ value 
Had donor infection No donor infection 
1 Age 34.7±13.0(19-60) 35.5±12.4(19-65) 0.63 
2 BMI 25.5±1.7(23.4-28.9) 25.1±1.5(21.6-28.3) 0.49 
TABLE 6. COMPARISON OF THE BASELINE CHARACTERISTICS OF CADAVERIC LIVER 
DONORS WHO HAD  BACTEREMIA WITH THOSE OF DONORS WHO DID NOT HAVE 
BACTEREMIA. 
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3 ICU stay 3.5±1.8 (2-8) 3.6±2.06(2-9) 0.86 
4 Inotropic support 2.3±0.5(2-3) 1.0±0.3(1-2) 0.05 
5 Total WBC count 
(per cumm) 
15978±6125(6700-30000) 8325±2920(2700-14000) 0.001 
6 Platelets count 
(Per cu mm) 
109857±51191(31000-205000) 106818±46361(12300-160000) 0.33 
7 Total blirubin (mgm/dl) 1.2±0.81(0.44-2.6) 0.96±0.5(0.45-2.3) 0.40 
8 ALT(U/dl) 256.4±102(45-1400) 115.3±88.7(42-320) 0.01 
9 Blood urea(mgs/dl) 49.9±15.01(23.5-74.4) 46.5±8.5(23.7-61.4) 0.03 
10 Serum creatinine(mgs/dl) 1.44±0.7(0.73-3.2) 0.9±0.35(0.3-2.0) 0.01 
11 Serum sodium(Meq/L) 147.9±8.6(132.3-163.4) 146.4±7.1(136-164.3) 0.81 
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AGE: 
 
 
 
Mean age of donor is 35.1±13.19 , with range from 19 to 65 yrs. Six donors 
were more than 50 yrs. Only three donors were female. Average BMI was 
25.2±1.5, with range from 21.6 to 28.9. Thirteen were alcoholics. Five donors were 
diabetics (15.1 %). All patients were managed in ICU.  
 
 
 
 
15 
20 
25 
30 
35 
40 
45 
50 
Had donor 
infection 
No donor 
infection 
34.7 35.5 
DONOR AGE (in years) 
Had donor 
infection 
No donor infection 
p-0.63 
6 
27 
DONOR AGE 
P value  
Univariete - 
0.13 
Multivariete- 
0.631 
Fig. 1.Donor age  Fig.2. Donor age and donor infections 
< 50 years 
>50  years 
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INOTROPE SUPPORT:  
 
 
Initially all donors were heamodynamically unstable and  received inotropic 
supports. Sixteen donors(48.5%) maintained with more than one inotrope . One 
donor sustained cardiac arrest and revived . 
 
 
 
 
 
0 
0.5 
1 
1.5 
2 
2.5 
Had donor infection No donor infection 
INOTROPIC SUPPORTS(n) 
Had donor infection 
No donor infection 
p- 0.05 
Fig.3. Inotropic support and donor infections 
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ICU STAY:  
 
 
     Mean ICU stay was 3.57±1.89, with range from 2 to 9 days. Twenty 
two(66.6%) stayed more than 48 hrs. For donors excluded due to sepsis with 
haemodynamic   instability , The mean average ICU stay was 5.8±1.2 days. 
DONOR CULTURE:  
 
0 
5 
10 
15 
20 
25 
DONOR 
ICU 
STAY 
> 2 days ≤ 2 days 
23 
10 
DONOR ICU STAY 
> 2 days 
≤ 2 days 
P value  
Univariete 
- 0.23 
Multivarie
te - 0.86 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Had donor 
infection 
No donor 
infection 
3.5 3.6 
DONOR ICU STAY 
Had donor 
infection 
No donor 
infection 
p- 0.86 
0 
5 
10 
15 
20 
DONOR 
CULTURE 
STATUS 
POSITIVE  NEGATIVE 
14 
19 
DONOR CULTURE STATUS NEGA…
   P value - 
0.035 
Fig. 4. Donor ICU stay and infections Fig. 5. Donor infections 
Fig. 5. Donor cultures status 
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S.no                                                                     
CULTURES 
No of positive 
growth 
1 Blood 11 
2 Urine 3 
3 Peritoneal fluid 2 
4 Tracheal fluid 1 
5 Perfusion fluid 0 
                                                                                                                                            
Total 
17
 
     Fourteen donor(42.4%) had bacterial infection. Eleven blood culture, Three 
urine culture, two tracheal fluid culture and one peritoneal fluid culture had 
bacterial growth.  
BACTERIAL ORGANISMS: 
S .no  Bacterial growth Numbers 
1 Single organism 10 
2 Polymicrobial organisms 4 
3 Gram positive organisms 3 
4 Gram negative 
organisms 
15 
 TABLE 7.  DONOR CULTUREs 
TABLE 8. BACTERIAL ORGAINISMS 
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Three culture shown gram positive organisms and gram negative 
organisms(83.3%)were found in fourteen cultures. Four donors had multiple 
organisms. 
BLOOD INVESTIGATIONS : 
  
Donors blood parameters  Mean with SD Range  
Hb (gm/dl ) 10±2.6 8.2- 15.6 
Total WBC (per cumm) 11862±5711 2700 - 30000 
Platelets(per cumm) 96039±45828 12300- 160000 
Blood urea(mgs/dl) 47.9±12.3 23.5 – 74.4 
Serum creatinine (mgs/dl) 1.14±0.58 0.3 – 3.2 
Total bilirubin (mgs/ dl ) 105±0.64 0.44- 2.6 
ALT (u/dl ) 175±95.6(42-1400) 42-1400 
Serum sodium(meq/l) 147±7.44 132.3 – 64.3 
 
 
TABLE. 9 . BLOOD PARAMETERS   
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RECIPIENTS : 
 
Seri
al 
no. 
Recipient 
variables 
N Mean ±SD( 
range) 
                       „p‟ value 
Univariat
e 
analysis  
Multivariate analysis  
pertaining to (Recipient 
factors) 
Same 
organis
ms 
Morbid
ity 
Mortal
ity 
1 Age : 
More than 
50 yrs 
Less than 
50 yrs 
 
 
12 
 
21 
 
47.12 
±10.6(16- 65) 
0.28 0.18 0.63 0.56 
2 Sex: 
Male 
Female 
 
28 
5 
 
 
- 
0.4 0.37 0.62 0.03 
3 BMI   - 25.248±1.53(
21.6-28.9) 
0.19 0.08 0.76 0.71 
4 DCLD: 
Cirrhosis 
Non 
cirrhosis 
 
28 
5 
 
 
- 
0.4 0.37 0.12 0.57 
       TABLE 10. The Baseline Characteristics Of Recipients Of Cadaveric Liver Transplantation 
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5 Cirrhosis 
complicati
ons 
(SBP/HE/
HRS) 
12(36.4
%) 
- 1.0 0.912 0.63 0.11 
6 Diabetes 
Mellitus 
9 - 1.0 0.91 0.44 
 
0.38 
7 MELD  - 18.9±3.15(12
-25) 
0.875 0.34 0.14 0.31 
8 Cold 
Ischemia 
Time 
- 377.12  
±68.16(300- 
500 ) 
0.685 0.22 0.002 0.14 
9 Recipient 
infections 
17(51.5
%) 
- 0.227(0.0
03) 
0.22(0.
08) 
0.124 0.33 
10 Infection  
both in 
donor and 
recipient 
9(27.3
%) 
- 0.73 0.002 0.001 0.29 
11 Recipient 
infection 
due to 
same donor 
organism 
3(9.1%
) 
- 0.23 - 0.005 0.25 
12 Morbidity 10(30.3
%) 
- 0.001 0.005 - 0.001 
13 Mortality  4(12.1
%) 
- 0.29 0.25 0.001 - 
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14 Hospital 
stay (days) 
All 
recipient  
For 
recipient 
with 
infection  
For 
recipient 
without 
infection 
- 
 
 
 
- 
 
13.7±4.5 
 
22.1±2.1 
 
 
11.5±1.5 
 
 
0.05 - 0.09 - 
 
 
S.no Characteristic Recipient status „p‟ 
value 
Had donor 
infection 
No donor 
infection 
1 Age 44.7±5.8(16-55) 48.9±10.6(26-65) 0.18 
2 BMI 25.7±2.3(22-29.3) 24.6±2.08(21.2-
28.0) 
0.08 
3 MELD 19.8±2.4(16-25.2) 18.3±3.3(12-25) 0.34 
4 Cold Ischemia 
Time(minutes) 
383.6±71.2(300-
500) 
372.3±67.6(300-
480) 
0.22 
5 Warm ischemia 91.07±11.6(65- 87.9±14.4(65- 0.13 
TABLE 11 . Comparison of the baseline characteristics of recipients of cadaveric liver transplants obtained 
from donors who had bacteremia and donors who did not have bacteremia. 
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time(minutes) 110) 120) 
6 Recipient infections(n) 9 8 0.33 
7 Recipient infection due to 
same donor organism(n) 
3 nil 0.005 
8 Morbidity(n) 8 2 0.005 
9 Hospital stay(days) 16.4±6.5 12.2±2.6(10-18) 0.11 
10 Mortality(n) 3 1 0.25 
 
Thirty three patients underwent deceased donor liver transplantation. Twenty 
eight (88.2%)were male and five female .  
AGE: 
 
 
12 21 
RECIPIENT - AGE 
P value  
Univariet
e - 0.28 
Multivari
ete- 0.18 
30 
35 
40 
45 
50 
55 
60 
Had donor 
infection 
No donor 
infection 
44.7 48.9 
RECIPIENT AGE 
Had donor 
infection 
No donor 
infection 
Fig.7. Recipient age and donor inefctions 
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Age range from 16 to 65 yrs with mean of 47.1±10.3.  
BMI was 21.2 to 29.3 with mean of 25.1±2.9.  
INDICATIONS: 
 
Serial 
no. 
INDICATIONS  
 
Number of patients  
1 Cryptogenic 14 
2 Viral  (HBV – Hepatitis B virus, 
HCV- Hepatitis C virus) 
9 (HCV – 3 & 
HBV - 6) 
3 Auto immune  1 
4 NCPF 1 
5 Secondary biliary cirrhosis 1 
6 Primary biliary cirrhosis 1 
7 NFLD 1 
8 Budd-Chiari Syndrome  2 
9 Hepatoma (denova origin) 
        (On cirrhosis background) 
3 
( 8) 
                                                                                  
Total 
33
 
TABLE 12. INDICATIONS FOR LIVER TRANSPLANTATION 
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Twenty eight had decompensated  liver disease. Three underwent 
transplantation for hepatoma de ova origin and two for acute fulminat liver failure 
due to Budd-Chiari Syndrome. Twelve had history of either SBP(Spontaneous 
bacterial peritoitis ) or HRS(Hepatorenal syndrome) or HE(Hepatic 
encephalopathy) or coagulopathy (complications of chronic liver disease and 
associated portal hypertension). Nine recipients were diabetic. 
MELD SCORE : 
MELD of the recipient : Mean was 18.9±3.2(12-25) . p-0.34 
 
 
Preoperative blood culture of  two recipients  had growth . since it was skin 
commensals , therefore  considered as insignificant. 
17 
18 
19 
20 
Had donor infection No donor infection 
19.8 
18.3 
MELD 
Had donor infection 
No donor infection 
P-0.34 
Fig .8. MELD and donor infections  
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PERFUSION FLUID: HTK (Histidine-Tryptophan-Ketoglutarate) solution was 
used as organ perfusion fluid in all donor liver as perfusate.  
COLD ISCHEMIA TIME : Cold ischemia time was from 300 to 500 minutes 
with mean value of 377.1±68.15 minutes. (p- univariate analysis : 0.003, 
multivariate analysis:0.224) 
WARM ISCHEMIA TIME: Warm ischemia time was from 65 to 120 minutes 
with mean value of 89.2±12.9 minutes. P- 0.739 
RECIPIENT INFECTION STATUS: 
 
 
Seventeen recipients  had bacterial growth in cultures in first week . One had 
fungal growth (candida albicans )in blood culture. 
0 
3 
6 
9 
12 
15 
18 
21 
24 
RECIPIENT 
CULTURE 
STATUS 
POSITIVE NEGATIVE 
17 16 
RECIPIENT  INFECTION  POSITIVE 
NEGATIVE 
P value  
Univariete - 0.003 
Multivariete- 0.082 
Fig .9. Recipient infections 
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S.no            CULTURES No of positive growth 
1 Blood 7 
2 Urine 3 
3 Peritoneal fluid 3 
4 Sputum 4 
5 Bile 1 
6 Wound 1 
                                                                                                                                                   
Total 
19 
Seven blood , three urine , three peritoneal fluid ,four sputum ,one bile and 
one wound culture had shown bacterial growth.  
GRAM STAINING STATUS: 
 
 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
Gram 
positive  
Gram 
negative 
single 
organism 
Multiple 
organisms 
4 
17 13 
4 
Bacterial infection 
Gram positive  
Gram negative 
single organism 
Multiple organisms 
TABLE 13.RECIPIENT’S CULTURE STATUS 
Fig. 10. Bacterial organisms 
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 Gram positive infection was seen in four cultures . Gram negative 
organisms were seen in seventeen cultures. Four cultures grown poly microbial 
bacterial organisms and another one(peritoneal fluid)had associated fungal 
growth(candida albicans). 
 
 
Nine had infection in both donor and recipient.  
 
 
 
 
2 
4 
6 
8 
10 
12 
Had bacteremia Did not have 
bacteremia 
9 8 
RECIPIENT INFECTIONS 
Had bacteremia 
Did not have bacteremia 
P-0.002 
Fig. 11. Recipient infections and donor infections 
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Three  donor and recipients had same organisms. Transmission rate is 
9.1%.Two of the recipients  had same antibiotic sensitivity as in donor. One 
recipient had both bacterial and fungal growth in blood culture..  
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Fig. 12. Donor infection transmission 
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MORBIDITY: 
 
Ten(58.8%)had infection related morbidities related to bacterial sepsis, (P- 
0.005) No patients had primary graft failure , or vascular complications. 
MORTALITY: 
 
 
0 
2 
4 
6 
8 
Had donor 
infection 
No donor 
infection 
8 
2 
RECIPIENT  INFECTION RELATED 
MORBIDITY 
Had donor infection 
No donor infection 
0 
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1 
1.5 
2 
2.5 
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infection 
Had same 
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1 
RECIPIENT MORTALITY 
Had donor infection 
Had same donor 
organisms 
P-0.005 
P-0.33 
Fig. 13. Recipient infection and related morbidities 
Fig. 14. Recipient’s infection related 30 days mortality 
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Thirty day mortality of recipient due to bacterial sepsis was four. Three of 
them had infection since first week and also had donor infection . But only one of 
them shared same organism as in donor, p- 0.33.  
HOSPITAL STAY: 
 
 
     Mean hospital stay of recipient was 13.7±4.5 days , with range from ten days to 
twenty four days. Recipients without infectious complications had mean the 
hospital stay of 12.3±3.6days. Those had infection related complications had 
prolonged hospital stay was17.6±6.1 days . But Hospital stay of recipient with 
donor bacterial infection was 16.4±6.5 and for without donor infection was 
12.2±2.6(10-18) , p- 011. 
 
0 
5 
10 
15 
20 
Had donor infection Did not have donor 
infection 
16 12 
RECIPIENT HOSPITAL STAY(DAYS) 
Had donor infection 
Did not have donor 
infection 
  P- 0.11 
Fig . 15.Recipient’s duration of hospital stay 
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DISCUSSION 
Infection is the most common complication of orthotopic liver 
transplantations and a major cause of mortality. Bacterial infections are the most 
common infection in early post operative period. The majority (81%) of bacterial 
infections occur within  first two months after liver transplantation . 
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In the solid-organ transplantation, and particularly for liver transplantation, 
donor infections are not only transmitted to the recipient, the donor infection also 
may affect the donated liver‟s preservability and subsequent function in the 
recipient irrespective of the systemic consequences of the infection. In addition, 
infected organs  are less able to respond to the pathogens because of their 
immunosuppressive state.  
1 
 DONOR: 
In our study, fourteen donors (42.4%) had bacterial infection,(p- 0.035) 
which is very significant and nearly half of the recipients were exposed to donor 
infection. On analyzing the donor risk factors. In this study, age was not 
considered as an important factor for donor infections as only two of the older 
donor(Age above 50 yrs) had infection. Twenty seven donors were below 50yrs. 
Twelve of them developed infection P (0.86). 
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      Male/female ratio was 10:1. Most of the donors were young male. Twelve male 
and two female had infection (p –0.39).  Since of most the donors were in their 
younger age , not many medical co morbidities were found in  the donors. Only 
Five (15.2%) donors were diabetics. Two(40%) of them had infection ,(p –0.91) . 
     Regarding the mode of death in donors, majority of donors sustained brain 
death due to road traffic accident. Nearly forty percent of donors were alcoholic 
and about 72% of them were sustained injury under the influence of alcohol. Five 
among them had infection – (p -1.0 , 0.721 , 0.964). 
All the brain dead patients were treated in ICU for variable period. All 
underwent various invasive procedures like central venous  line insertion, arterial 
lines , tracheostomy and  urinary bladder catherisation. All  had ventilator support . 
It has been reported that comatose patients are commonly associated the risk of 
nosocomial pneumonia, especially if they are in ventilator support.
13,26,68
  
       Similarly ,  Bacterial  or fungal infection  are acquired  in the terminal  stage  
of  the donor's care in an intensive care unit (like vascular  access  infection,  
nosocomial  pneumonia,  bladder catheter-related infection)
 10,14
 
The European Prevalence of Infection in Intensive Care study has reported 
as 45% of ICU patients had 1 or more infections and 12% of them had 
bacteremias. 
70
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      Moreover, generally there is a depression in immunity level in brain dead, 
either due to brain injury itself or due to admission various immune suppressants 
like steroids.  It is very difficult in diagnose or suspect sepsis in brain dead . 
Because they exhibit clinical signs as in sepsis due to head injury as the result of 
alteration taking place in central control lead to features of SIRS(Systemic 
inflammatory response syndrome) . Paradoxically using drugs like steroids masks 
the signs of clinical sepsis. Conversely  in brain-injured  patients the hyperthermia  
and hemodynamic instability are often due to brain damage rather than infections.
10
 
     About fifteen donors were disqualified for harvesting organs due to 
profound sepsis. In these patients, the mean average ICU stay was 5.8±1.2 days . 
For donors who were clinically stable in whom organs harvested., the mean ICU 
stay of donors was 3.57±1.89, with range from 2 to 9 days. Twenty three(69.7%) 
donors were treated in ICU for more than 48 hrs . Ten (43.5%)of them had 
infection (p - 0.86). This result is statistically insignificant. The possible 
explanation is these stable donors were not completely representing the infections 
in brain dead since  others  with frank sepsis were excluded. 
      Many studies have reported about the risk factors bacterial infection in 
donors. Among them , duration of ICU stay is important factor. ICU stay increases 
the risk of nosocomial infection and that 33%  to  45%  of  all  nosocomial  
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bacteremias  occur  in  these patients.  But the upper limit of ICU stay in which less 
donor infections reported are extremely variable.
6 ,67
 
      In most of the studies,  ICU stay of three or more days is a significant 
predictor of donor infection. 
11,35
 In some studies, ICU stay of  more than seven 
days is a significant predictor of donor infection.
74
 
Vincent JL et al described seven risk factors for ICU-acquired infection: 
increasing length of ICU stay (> 48 hours), ventilator support, trauma, central 
venous, pulmonary artery catheterisation, and urinary catheterization, and stress 
ulcer prophylaxis 
74
.  
Varying results  from these studies regarding duration of ICU stay  indicate 
that  it is very difficult to define the upper limit for ICU stay which depends upon 
many factors like ICU management policies, trained personals and  facilities.   
      Since most of the donors were haemodynamically unstable, all received 
inotrope support. Seventeen donors received single  inotrope support. Twelve 
received two inotropes and Four received three inotropes support. Donors treated 
with single inotrope , not developed infection. whereas Ten (83.3%)donors who 
received two inotrope and all four donors who received three inotropes had donor 
infection (p  - 0.001). Wu TJ et al reported as in brain dead, haemodynamic 
instability and changes in various organ homeostasis are due to brain injury and 
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sepsis and the necessity of  multiple inotropes are directly proportionate to the 
extent of injury due to sepsis. Both revived cardiac arrest and inotropic supports 
were the independent factors to predict donor infection. 
74
 
      Elevated total WBC counts, low platelet count, elevated hepatic enzymes 
and renal parameters are important indicators of bacterial sepsis.  Nineteen(57.6%) 
donors had elevated total WBC counts . Thirteen (68.4%)of them had infection.( P- 
0.001).  Eleven donors (33.3 %)had platelet counts below 100,000. Six(54.5%) of 
them developed infection. P- (0.33). Five(15.2%) donors had elevated total 
bilirubin . Two of them contracted infection. (p-0.40) 
       Liver enzymes(ALT) were elevated in fifteen donors(45.5%). Ten 
(66.7%)of them had infection .p- (0.01). In this group, recipient‟s infection 
morbidities also increased.(p-0.01).   Twelve (36.4%)had elevated blood urea. 
Eight (66.7%) of them had infection. (p- 0.03)Nine(27.3%) had elevated serum 
creatinine. Seven (77.8%)had infection ,(p- 0.01) Eighteen(54.5%)had 
hypernatremia.  Eight(44.4%) of them had infection. (p-  0.81).  
      Generally sepsis  associated with elevation other  systemic parameters like 
elevated WBC  counts , Blood urea ,serum creatinine and liver enzymes .In our 
study elevated WBC counts, blood urea , serum creatinine and elevated liver 
enzymes were found in infected but clinically stable donors. Drop in platelet 
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counts and elevated serum sodium were not significantly associated with donor 
infection. 
      After analyzing all the factors , duration of ICU stay , number of inotropes 
required to main haemodynamic stability, elevated WBC  counts , Blood urea 
,serum creatinine and liver enzymes are factors throw the light to suspect donor 
infection who are otherwise clinically stable without signs of overt sepsis. 
RECIPIENT: 
      When a recipient gets infection in the early post liver transplantation period , 
the sources could be from donor or contamination during donor surgery or 
recipient surgery ,or post operative ICU. Since incidence of contamination is 
insignificant and negligible. Similarly contracting infection from transplant ICU  in 
first week after transplantation is uncommon.  Naturally ,the main source is donor 
unless proved otherwise. 
      Seventeen(51.5%) had infections (p- 0.003). Fifteen recipient were  male 
(88.2%)p- 0.37. The mean BMI was 25.08±2.16, (range : 21-29) (p- 0.08). Six 
recipients were more than 50 yrs in age . p-, (0.18). MELD – Mean : 18.97 ± 3.15 
(range : 12-25 ) ;(p- 0.34).  
      Twenty eight recipients underwent liver transplantation for chronic liver 
disease (84.8%); Fourteen had infection in first week (50%); ( p- 0.37).  In our 
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study, the major indication for liver transplantation was decompensated liver 
diseases. Most common  indication was cryptogenic DCLD followed by viral 
etiology. In viral liver diseases , HBV related DCLDs were predominant. 
Regarding HCC , Most the transplantation was done for HCC with cirrhosis 
background .   
      Preoperatively ,Twelve recipients(36.4%) were treated for cirrhosis related 
complication like SBP, HRS or for hepatic encephalopathy. Seven(58.8%) had 
infection . Only one(8.3%) of the recipient had same organism as found in donor . 
(0.91).Ten(30.3%) recipients were diabetic. One recipient developed donor 
infection, p-0.91. None of the recipient‟s factors analysed in this study 
significantly associated with donor related recipient infections.  
      Mean cold ischemia time of the donor organ was 377.12±68.15(range : 300-
500 minutes) ; p-0.33.  Paya CV et al
 59
  reported  as prolongation of cold ischemia 
time certainly affect the quality of the organs which become susceptible for 
infection. Similarly, the main risk factor predisposing to bacterial infection appears 
to be the duration of the transplantation operation, especially beyond 12 hours.  
      Duration of cold ischemia time depends upon various factors like type of 
liver transplantation deceased donor /living donor), experience of the surgical team 
, Coordination between donor institute / transplant team  , distance between place 
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of donor and recipient surgery, transport facilities. All our case were deceased 
donor   liver transplantation .We use to get organs from various government and 
private institutions at various distance which range from 6 to 200 kilometers. In the 
initial period of our programme , the cold ischemia time was longer which 
presently reduced considerably including the total duration of surgery. The mean 
cold ischemia time in our study was only 377 minutes and no major difference 
between two groups. But recipient‟s infection morbidities were more common in 
donor organ with prolonged cold ischemia time indicating vulnerability of the 
harvested organ for infection in post operative period.   
      Warm ischemia time : mean 89.2±12.9 minutes ; p-0.739 . Carlos Lumbreras 
et al reported that  prolonged  warm ischemia time was significantly associated 
with donor bacteremia 
. 10
 Recent studies show a cumulative negative effect 
induced by prolonged Cold ischemia time and Warm ischemia time
 8,32,69 .
  
     The harvested organ contamination also a source for recipient infection . In 
our study, though none of our perfusion fluid had bacterial growth , many studies 
reported the cultures of perfusion fluid and transport medias may be  positive  in  
up  to 40%  . Most  of  positive  cultures are  caused by  non virulent  skin  floor 
have  correlated  poorly  with  the  occurrence  of  post transplant  infections.
22
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      The type of bacterial infection found in donor transmitted recipient infection 
varies in literature. Paya et al reported as gram-negative organisms are more 
common (66%) organisms found in recipients.
 59
 In our study, Most of the 
organisms found in donor and recipient were gram negative organisms. (73.7%).  
All organisms found in donor transmitted recipients were gram negative 
organisms.  
      Though more than half the recipients had infection in first week and nine 
had both donor and recipient infection Seven(77.8%)of nine had infection related 
morbidities. P- 0.001. Only three of them had same organisms, traceable to donor 
with same antibiotic sensitivity. Though the rate of transmission is 9.1%, it is 
statistically insignificant (p-0.227) and must be  interpreted as the chance for 
transmission of donor infection is very remote. Low intensity infection, Low 
virulent organisms , preemptive antibiotic therapy both in donor and recipient and 
new unfavorable environment 
83
 in recipient could be the reasons for low infection 
transmission to recipient.  
      All three recipients (100%) had infection related morbidities p-0.02 , But no 
one had major complications like hepatic artery thrombosis , donor organ 
dysfunction or anastomotic disturbance. 
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      It appears significance of transmission bacterial infection to recipient  from 
stable and adequately treated donor is negligible. Since all donors and recipient 
were treated with broad spectrum antibiotics empirically and then to specific 
antibiotics according culture sensitivity , there must be definite role  for antibiotic 
in preventing bacterial infection from donor to recipient. Moreover it is not known 
some organisms which not shown any growth in donor cultures and  could grow as 
predominant organisms in new recipient environment and produce infection related 
morbidities. So all the early recipient infection(in first week) must be viewed as 
source from donor unless otherwise proofed or excluded other possibilities. 
      Though donor derived bacterial infection in recipient is not statically 
insignificant , Transmission of infection from donor produce significant infection 
related morbidities. Since knowledge about  the source, virulence and antibiotic 
sensitivity pattern  of donor related recipient infection  are available in time which 
will help to avoid major complication like hepatic artery thrombosis , arterial  
anastomotic disruption or poor  function  of  the  graft . 
15,16,24,25,27,57,72
 
      Thirty day mortality due to first week bacterial infection was four. Three of 
them had infection since first week. Two of them also had donor infection . But 
only one of them shared same organism as in donor, p- 0.33. His blood had both 
bacterial(MRSA strain of staph. aureus)  and fungal growth (candida albicans). 
This explain the severity of infection due to highly virulent bacteria and combined 
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fungal sepsis. In this study, 30-day mortality of patients receiving organs from 
donors with infection was insignificant when to compare with recipient of organs 
from uninfected donors. This suggests that there was no signiﬁcant compromise of 
the preservability or subsequent function of organs from infected donors. Hsin-Yun 
Sun, et al 
41 
reported as if pretransplant infections that have been adequately treated 
they do not pose a significant risk for poor outcomes in recipients, including post 
transplant mortality. 
      Hospital stay : Mean 13.79±4.6 days ; range : 10-24 days. Recipient with 
infectious complications stayed twice the duration as recipient without infections 
or related complications. Hence, it is obvious that Infectious complications in 
recipients increases the hospital stay and also medical expenditure. 
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CONCLUSION: 
By analyzing all the factor in donors and recipients, It can be concluded as : 
 Duration of ICU stay , number of inotropes required and its dose  are well 
associated with donor infection.  
 Total WBC count, elevated liver enzymes and renal parameters are 
important risk indicators for donor infection. 
 Cold ischemia time plays a major role in recipient infection related 
morbidities by rendering the organs vulnerable to infection.  
 Routine usage of broad spectrum antibiotic followed by appropriate 
antibiotics prevent effective transmission infection from donor to recipient. 
22,58
   
 The rate of infection  transmitted from donor to recipient is neglible. So 
infection in clinically stable donors are not a contraindication to harvest the 
organs.  
 But the same time , whenever the donor infection is transmitted to recipient , 
it produce significant major infection related morbidities.  
 Though the mortality rate was statically insignificant , it increase recipient‟s 
hospital stay and medical expenditure. 
 Appropriately  treated  pre transplant donor and recipient  infections do not 
adversely affect outcome including the risk of post transplant infections or 
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mortality after liver transplantation. Over all , by not rejecting the clinically 
stable but infected donors , expand the donor pool
51,55  
. 
 Many literature supporting the organs donation from donor with sepsis . 
Most of them are from western studies which is not representing the 
developing countries . Scenarios in developing countries like India is totally 
different especially standard of ICU care , medical facilities, surgical 
experience. This study is from the a government institute typically 
representing the rest of country. 
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 LIMITATIONS: 
 
 Power of the study is weak due to  smaller group of patients. 
 Management policy of brain dead patients differ from institute to institute   
which leads to selection bias in assessing the risk factors for donor 
infections.   
 Regarding donor infection, all the brain dead patients should be included in 
the study to find out the factors influencing donor infection. This study 
analyzed only about the stable donor without clinical signs of infection. 
They were only partly representing the cadaver pool. 
 In this study , it was considered (on based on literature evidence) 82as  
recipient infection in first week after transplantation was exclusively due to 
donor source. There might be possibility of recipient source also. To address 
this bias , only same organism with same antibiotic sensitivity found in both 
donor and recipient were considered as definite evidence of transmission, 
Though identifying the bacterial genome is the only way to ensure the 
infection transmission which is not available in present clinical setup. 
 
 DONOR PROFORMA FORM 
 
DONOR NAME:                             AGE:                                        SEX: 
IPNO:                                         DATE: 
Mode of death:                                                                                                                                  
Date of accident: 
Alcoholic:        yes / no. 
Co morbidities: 
Duration of icu stay: 
Hypotension: 
No of inotropes used: 
History of  cardiac arrest: 
Antibiotics and duration of treatment: 
UNSUSPECTED  BACTERIAL INFECTION IN DECEASED DONORS AND ITS 
IMPACT ON IMMEDIATE POST OPERATIVE INFECTIONS IN LIVER 
RECIPIENTS. 
DEPARTMENT SURGICAL GASTROENTEROLOGY , GOVT. STANLEY HOSPITAL , CHENNAI. 
Surgery/ invasive procedure: 
Perfusion  fluid: 
Blood transfusions: 
Blood culture: 
Urine culture: 
Throat swab: 
Tracheal aspirate: 
Other cultures: 
CLINICAL FEATURES: 
BLOOD INVESTIGATIONS: 
Complete haemogram: 
Liver function test:: 
Blood urea: 
Serum creatinine: 
Serum electrolytes: 
DONOR SURGERY DETAILS : 
Duration of surgery: 
Intraoperative events: 
Perfusion fluid used in no: 
Organ transport time: 
Cold ischemia time: 
 
OTHER REMARKS: 
 
                                                                                                                                                
VERIFIED BY 
 
 
 
 
 
  
 
 
 
RECIPIENT PROFORMA FORM 
 
RECIPIENT NAME :                                        AGE:                                SEX:                    
IP NO :                                                                                                          DATE: 
Diagnosis :                      
Indications for liver transplantation : 
CTP score: 
MELD: 
Pre op events of complications:  
Associated malignancies: 
Pre op culture status: 
Duration of recipient surgery:  
Warm ischemia time: 
UNSUSPECTED  BACTERIAL INFECTION IN DECEASED DONORS AND 
ITS IMPACT ON IMMEDIATE POST OPERATIVE INFECTIONS IN LIVER 
RECIPIENTS. 
DEPARTMENT SURGICAL GASTROENTEROLOGY , GOVT. STANLEY HOSPITAL , CHENNAI. 
 
DEPARTMENT SURGICAL GASTROENTEROLOGY , GOVT. STANLEY HOSPITAL , CHENNAI. 
 
 
Total duration surgery:  
Blood loss:  
Blood transfusion:  
Intra operative  events:  
Immunosuppressants : 
Antibiotics: 
 
CLINICAL FEATURES:  
 Morbidities and treatment details: 
Acute rejection: 
Vascular complications: 
Mortality details: 
Hospital stay (duration in days) 
 
 
 BLOOD INVESTIGATIONS: 
Complete haemogram: 
Liver function test:: 
Blood urea: 
Serum creatinine: 
Serum electrolytes:                                                                      Other tests: 
POST OP CULTURE STATUS (Organisms/Antibiotic sensitivity): 
Urine:                                                                                                              Blood: 
Bile:                                                                                             Wound discharge: 
Tracheal fluid:                                                                       Intra abdominal fluid: 
Other cultures: 
 
                                                                                                                                                           
VERIFIED BY 
 
  
 
 
 
 
 
 
 
ANNEXURE TABLE CHARTS 
 DONOR 
NAME 
  
AGE 
  
  
SEX 
  
  
BMI 
  
  
ALCOHOLIC 
  
           DM  
DURATION  
OF ICU 
 STAY 
> 2 
DAYS 
  
  
NO OF  
INOTROPES 
  
CULTURE  
POSITIVITY 
  
TC 
  
  
PLATELETS 
  
  
T 
BILIRUBIN 
  
INCREASED 
LIVER 
ENZYMES 
BLOOD  
UREA 
  
ELEVATED 
UREA 
  
S.  
CREATININE 
  
ELEVATED  
CREATININE  
  
S. 
NA+ 
  
  
Karthick 24 M 26 YES NO 3 YES 1 NO 4500 123000 0.7 NO 45.9 NO 0.8 NO 136.4 
Suganya 21 F 24 NO NO 5 YES 3 YES 18300 45000 1.2 YES 63.1 YES 1.5 YES 156.8 
PALANIVEL 35 M 25 YES NO 5 YES 1 NO 7500 160000 0.7 NO 47.3 NO 0.8 NO 142.1 
Jayabharathi 23 F 22 NO NO 5 YES 1 NO 8600 146000 0.8 NO 47.9 NO 0.8 NO 136 
Parthiban     46 M 26 NO NO 2 NO 1 NO 14000 150000 1.2 YES  52.3 YES 1.2 NO 156 
Kuppan 45 M 24 YES NO 2 NO 1 NO 9600 145000 1 NO 41 NO 0.9 NO 138 
Perumal   30 M 25 NO NO 3 YES 1 NO 7400 12300 1.1 NO 47.2 NO 0.8 NO 144 
Prabakaran    29 M 26 YES NO 9 YES 1 NO 8900 140000 0.89 NO 46.3 NO 0.8 NO 142 
Gaja      50 M 27 YES YES 4 YES 2 NO 10000 136000 1 NO 36.2 NO 1.1 NO 150 
Kasinathan  40 M 26 NO NO 6 YES 2 YES 11,400 96,000 0.9 YES 44.85 NO 0.88 NO 144.4 
Thadi 
themothi          20 F 24 NO NO 2 NO 3 YES 15000 86000 1 YES 50.2 YES 0.78 NO 149.3 
Mohan       25 M 24 NO NO 8 YES 1 NO 6700 120000 0.8 NO 42.3 NO 0.45 NO 140 
Deysingh              32 M 26 NO NO 2 NO 2 YES 16,000 103000 2.5 YES 50.78 YES 1.19 NO 145 
Jothi  60 M 24 NO YES 4 YES 2 YES 6,700 128000 1 YES 74.36 YES 1.78 YES 148.6 
Annamalai  36 M 25 YES NO 2 NO 1 NO 2,700 57,000 0.94 YES 61.4 YES 2 YES 152.1 
Sekar                   24 M 23 NO NO 2 NO 1 NO 10,600 113000 0.99 YES 60.12 YES 1.07 NO 164.3 
Ragavan        50 M 25 YES YES 3 YES 2 YES 16,000 80000 2.6 YES 63.2 YES 1.3 YES 149 
Shankar  38 M 29 NO NO 3 YES 2 YES 23,600 161000 0.74 YES 73.89 YES 3.23 YES 132.3 
Arun  22 M 25 NO NO 3 YES 1 NO 12,800 84000 2.1 YES 56.2 YES 1.3 YES 146 
Sivaprakasam 35 M 26 NO NO 3 YES 2 YES 22,200 205000 0.54 NO 36.46 NO 1.09 NO 155.6 
Gurulingam      48 M 27 YES NO 2 NO 3 YES 10,800 104000 0.44 YES 54.1 YES 1.57 YES 163.4 
Mani kandan      21 M 24 YES NO 8 YES 2 YES 30,000 111000 0.6 NO 23.54 NO 0.73 NO 155.7 
Mani kandan      19 M 24 NO NO 3 YES 3 YES 16,100 31,000 2.6 YES 58.83 YES 2.04 YES 138 
Siva doss     19 M 25 NO NO 5 YES 1 NO 10,560 12600 0.5 NO 45.6 NO 1 NO 150 
Jagan           28 M 26 NO NO 3 YES 1 NO 8,900 120000 1.2 NO 48.2 NO 0.9 NO 147 
Jagadesan           26 M 26 NO NO 3 YES 2 YES 12,200 143000 0.51 NO 35.65 NO 1.13 NO 147.9 
pari          39 M 27 YES NO 3 YES 2 YES 14,000 190000 1.15 YES 44.87 NO 2.16 YES 139.3 
Ram babu          36 M 28 YES NO 3 YES 2 NO 7,700 101000 0.45 NO 44.5 NO 0.97 NO 151.7 
srinivasan  23 M 24 NO NO 3 YES 1 NO 4,200 64,000 0.54 NO 23.69 NO 0.71 NO 146 
arjunan   55 M 24 NO YES 2 NO 1 NO 11,600 156000 2.3 YES 45.9 NO 1.1 NO 148 
devaraj  60 M 26 YES YES 2 NO 1 NO 9,000 100000 0.6 NO 45.6 NO 0.4 NO 145 
David 37 M 25 YES NO 2 NO 2 YES 11,400 55,000 0.5 NO 24.2 NO 0.75 NO 145.2 
Kumar 65 M 26 NO NO 3 YES 1 NO 12,500 90000 0.5 NO 45.3 NO 0.3 NO 147 
DONOR DETAILS 
BMI – Body Mass Index, DM – Diabetes Mellitus, MELD – Model for End stage Liver Disease, TC –Total WBCCount 
RECIPIENT  
NAME  
  
AGE  
  
  
SEX 
  
  
BMI 
  
  
CIRRHOSIS 
  
  
MELD 
  
  
PRE OP EVENTS 
 OF 
COMPLICATIONS 
(SBP/HRS) 
DM 
-  
YES/ 
NO 
  
PRE OP  
CULTURE  
STATUS  
COLD   
ISCHEMIA 
TIME  
WARM   
ISCHEMIA 
TIME 
PRIMARY  
GRAFT 
 FAILURE 
ACUTE  
REJECTION 
  
VASCULAR  
COMPLICATIONS  
  
POST OP 
 CULTURE  
POSITIVITY 
STATUS 
RETRANSPLANTATION 
  
  
Fathima       42 F 23 YES 15 NO NO NIL 300 80 NO NO NO YES NO 
Samandhi       40 F 22 YES 22 NO YES NIL 420 110 NO NO NO YES NO 
Ravichandran  43 M 23 YES 13 YES NO NIL 310 110 NO NO NO NO NO 
Chandrasekar      51 M 27 YES 15 NO YES NIL 450 90 NO NO NO YES NO 
Sarathy        35 M 28 YES 16 NO NO NIL 320 70 NO NO NO NO NO 
Dhanasekar     51 M 26 YES 22 NO NO NIL 310 80 NO NO NO NO NO 
kadanandha              45 M 25 NO 17 YES YES NIL 420 65 NO NO NO YES NO 
Manickam            59 M 28 YES 12 NO NO NIL 360 70 NO NO NO NO NO 
Velu           50 M 22 YES 16 NO YES NIL 410 90 NO NO NO YES NO 
Moorthy    55 M 25 YES 19 NO NO NIL 500 100 NO NO NO YES NO 
Vijayaraghavan   50 M 29 YES 19 NO NO NIL 480 100 NO NO NO YES NO 
Vijayakumar    35 M 26 YES 19 NO NO NIL 480 90 NO NO NO YES NO 
Periyasamy   48 M 26 NO 17 YES YES NIL 420 90 NO NO NO YES NO 
Nataraj                    35 M 23 NO 19 NO NO CONS  450 65 NO NO NO YES NO 
Raju               60 M 26 YES 20 NO YES NIL 480 90 NO NO NO YES NO 
Paranthaman                     55 M 23 YES 22 YES NO NIL 390 90 NO NO NO YES NO 
Deivasigamani    50 M 28 YES 23 YES YES NIL 400 90 NO NO NO YES NO 
Balamanoharan                     55 M 27 YES 19 YES NO 
blood - 
micrococci 450 100 NO NO NO YES NO 
ponvedha 
muthu  59 M 25 YES 17 NO NO NIL 300 120 NO NO NO NO NO 
Ramesh                    48 M 24 YES 21 YES NO NIL 400 100 NO NO NO YES NO 
Mani              42 M 24 YES 19 YES YES NIL 300 90 NO NO NO NO NO 
Jenifer charles             47 M 24 YES 19 NO NO NIL 320 80 NO NO yes NO NO 
Madhavi 47 F 29 NO 19 NO NO NIL 320 80 NO NO NO NO NO 
valluvamani             48 M 22 YES 19 YES NO NIL 450 100 NO NO NO YES NO 
Rangaraj             40 M 23 YES 20 NO NO NIL 320 100 NO NO NO NO NO 
Seran  51 M 27 YES 25 YES NO NIL 300 90 NO NO NO NO NO 
Govindan 42 M 25 YES 16 NO NO NIL 310 90 NO NO NO NO NO 
Damodharan  64 M 23 YES 21 NO NO 
URINE - 
KLEB 450 85 NO NO NO YES NO 
Velu  61 M 26 YES 16 YES YES NIL 315 70 NO NO NO NO NO 
jayagandhi  40 F 25 YES 19 NO YES NIL 300 80 NO NO NO NO NO 
Balchander  26 M 21 YES 24 NO NO NIL 360 90 NO NO NO NO NO 
Kalaiarasi  16 F 26 NO 21 NO NO NIL 300 90 NO NO NO NO NO 
Srinivasan 65 M 26 YES 25 YES NO  350 100 NO NO NO NO NO 
RECIPIENT DETAILS 
 COMPARISON DETAILS OF ALL DONOR’S AND RECIPIENT’S CHARECTERISTICS 
DONOR 
  
CULTURE 
 POSITIVITY 
ORGANISMS 
  
RECIPIENT  
  
CULTURE  
POSITIVITY 
SAME  
ORGANISM 
SAME  
SENSITIVITY 
INFECTION 
 IN BOTH 
MORBIDITITY 
  
MORTALITY 
  
DURATION OF  
HOSPITAL STAY 
Karthick NO NO Fathima       YES NO NO NO NO NO 13 
Suganya YES GP Samandhi       YES YES YES YES YES YES Mortality 
PALANIVEL NO NO Ravichandran  NO NO NO NO NO NO 12 
Jayabharathi NO NO Chandrasekar     YES NO NO NO NO NO 15 
Parthiban     NO NO Sarathy        NO NO NO NO NO NO 12 
Kuppan NO NO Dhanasekar     NO NO NO NO NO NO 10 
Perumal   NO NO kadanandha              YES NO NO NO NO NO 10 
Prabakaran    NO NO Manickam            NO NO NO NO NO NO 15 
Gaja      NO NO Velu           YES NO NO NO NO NO 13 
Kasinathan  YES GN Moorthy    YES NO NO YES YES YES Mortality 
Thadi themothi          YES GP,GN Vijayaraghavan   YES NO NO YES YES NO 24 
Mohan       NO NO Vijayakumar    YES NO NO NO NO NO 10 
Deysingh              YES GN Periyasamy   YES NO NO YES YES NO 23 
Jothi  YES GN,GN Nataraj                    YES YES NO YES YES NO 21 
Annamalai  NO NO Raju               YES NO NO NO YES YES Mortality 
Sekar                   NO NO Paranthaman                     YES NO NO NO NO NO 10 
Ragavan        YES GN Deivasigamani    YES NO NO YES YES NO 23 
Shankar  YES GN,GN Balamanoharan                     YES NO NO YES NO NO 12 
Arun  NO NO Ponvedamoorthy NO NO NO NO NO NO 11 
Sivaprakasam YES GN Ramesh                    YES YES YES YES YES NO 24 
Gurulingam      YES GN,GN Mani              NO NO NO NO NO NO 12 
Mani kandan      YES GN Jenifer charles             NO NO NO YES NO NO Mortality 
Mani kandan     YES GN,GN Madhan             NO NO NO NO NO NO 10 
Siva doss     NO NO valluvamani             YES NO NO NO NO NO 12 
Jagan           NO NO Rangaraj             NO NO NO NO NO NO 13 
Jagadesan           YES GN Seran  NO NO NO NO NO NO 10 
pari          YES GP Govindan NO NO NO NO NO NO 10 
Ram babu          NO NO Damodharan  YES NO NO NO YES NO 18 
srinivasan  NO NO velu  NO NO NO NO NO NO 10 
arjunan   NO NO jayagandhi  NO NO NO NO NO NO 13 
devaraj  NO NO Balchander  NO NO NO NO NO NO 11 
David YES GN Kalaiarasi  NO NO NO NO YES YES 11 
Kumar NO NO Srinivasan NO NO NO NO NO NO 12 
         GP- Gram positive , GN- Gram negative. 
 DONORS WITH INFECTIONS. 
DONOR 
NAME AGE SEX BMI ALCOHOLIC DIABETICS 
ICU 
STAY 
(DAYS) 
>2DAYS 
No 
OF 
INOTROPES 
TOTAL 
WBC 
COUNT 
PLATELETS 
COUNT 
TOTAL 
BILIRUBIN 
LIVER 
ENZYMES 
BLOOD 
UREA 
SERUM 
CREATININE SERUM Na+ 
Suganya 21 F 23.5 NO NO 5 YES 3 18300 45000 1.2 300 63.1 1.5 156.8 
Kasinathan 40 M 26.4 NO NO 6 YES 2 11,400 96,000 0.9 360 44.85 0.88 144.4 
Thadi themothi 20 F 24 NO NO 2 NO 3 15000 86000 1 105 50.2 0.78 149.3 
Deysingh 32 M 26.4 NO NO 2 NO 2 16,000 103000 2.5 140 50.78 1.19 145 
Jothi 60 M 23.6 NO YES 4 YES 2 6,700 128000 1 100 74.36 1.78 148.6 
Ragavan 50 M 25.4 YES YES 3 YES 2 16,000 80000 2.6 160 63.2 1.3 149 
Shankar 38 M 28.9 NO NO 3 YES 2 23,600 161000 0.74 200 73.89 3.23 132.3 
Sivaprakasam 35 M 26.1 NO NO 3 YES 2 22,200 205000 0.54 45 36.46 1.09 155.6 
Gurulingam 48 M 27 YES NO 2 NO 3 10,800 104000 0.44 180 54.1 1.57 163.4 
Mani kandan 21 M 23.5 YES NO 8 YES 2 30,000 111000 0.6 50 23.54 0.73 155.7 
Mani kandan 19 M 23.9 NO NO 3 YES 3 16,100 31,000 2.6 180 58.83 2.04 138 
Jagadesan 26 M 25.8 NO NO 3 YES 2 12,200 143000 0.51 60 35.65 1.13 147.9 
Pari 39 M 27.3 YES NO 3 YES 2 14,000 190000 1.15 310 44.87 2.16 139.3 
David 37 M 24.7 YES NO 2 NO 2 11,400 55,000 0.5 1400 24.2 0.75 145.2 
BMI – Body Mass Index 
 
 
 RECIPIENTS WITH DONOR INFECTIONS: 
RECIPIENT 
NAME 
  
AGE  
  
  
SEX 
  
  
BMI 
  
  
CIRRHOSIS 
  
  
MELD 
  
  
PRE OP EVENTS  
OF COMPLICATIONS 
(SBP/HRS) 
DM  
 YES/ NO 
  
PRE OP  
 CULTURE 
STATUS  
COLD  
ISCHEMIA 
 TIME  
WARM  
ISCHEMIA  
TIME 
PRIMARY  
GRAFT 
 FAILURE 
ACUTE  
REJECTION 
  
VASCULAR  
COMPLICATIONS  
  
POST OP CULTURE  
POSITIVITY 
 STATUS 
Samandhi       40 F 22 YES 22 NO YES NIL 420 110 NO NO NO YES 
Moorthy    55 M 24.6 YES 19 NO NO NIL 500 100 NO NO NO YES 
Vijayaraghavan   50 M 29.3 YES 19 NO NO NIL 480 100 NO NO NO YES 
Periyasamy   48 M 26.1 NO 17 YES YES NIL 420 90 NO NO NO YES 
Nataraj                    35 M 23.4 NO 19 NO NO CONS  450 65 NO NO NO YES 
Deivasigamani    50 M 28.3 YES 23 YES YES NIL 400 90 NO NO NO YES 
Balamanoharan                     55 M 27.4 YES 19 YES NO blood - micrococci 450 100 NO NO NO YES 
Ramesh                    48 M 23.6 YES 21 YES NO NIL 400 100 NO NO NO YES 
Mani              42 M 24.1 YES 19 YES YES NIL 300 90 NO NO NO NO 
Jenifer charles             47 M 24.3 YES 19 NO NO NIL 320 80 NO NO yes NO 
Madhavi 47 F 29 NO 19 NO NO NIL 320 80 NO NO NO NO 
Seran  51 M 26.7 YES 25 YES NO NIL 300 90 NO NO NO NO 
Govindan 42 M 24.5 YES 16 NO NO NIL 310 90 NO NO NO NO 
Kalaiarasi  16 F 26.4 NO 21 NO NO NIL 300 90 NO NO NO NO 
BMI – Body Mass Index, DM – Diabetes Mellitus, MELD – Model for End stage Liver Disease, TC – Total Count 
 
 
 
 COMPARISON OF INFECTED DONORS AND THEIR RECIPIENTS: 
DONOR 
  
CULTURE  
POSITIVITY 
RECIPIENT  
  
CULTURE 
POSITIVITY 
INFECTION  
IN BOTH 
SAME  
ORGANISM 
SAME  
SENSITIVITY 
MORBIDITITY 
  
MORTALITY 
  
DURATION 
OF 
HOSPITAL 
STAY 
Suganya YES Samandhi       YES YES YES YES YES YES Mortality 
Kasinathan  YES Moorthy    YES YES NO NO YES YES Mortality 
Thadi themothi          YES Vijayaraghavan   YES YES NO NO YES NO 24 
Deysingh              YES Periyasamy   YES YES NO NO YES NO 23 
Jothi  YES Nataraj                    YES YES YES NO YES NO 21 
Ragavan        YES Deivasigamani    YES YES NO NO YES NO 23 
Shankar  YES Balamanoharan                     YES YES NO NO NO NO 12 
Sivaprakasam YES Ramesh                    YES YES YES YES YES NO 24 
Gurulingam      YES Mani              NO NO NO NO NO NO 12 
Mani kandan      YES Jenifer charles             NO YES NO NO NO NO Mortality 
Mani kandan     YES Madhan             NO NO NO NO NO NO 10 
Jagadesan           YES Seran  NO NO NO NO NO NO 10 
pari          YES Govindan NO NO NO NO NO NO 10 
David YES Kalaiarasi  NO NO NO NO YES YES 11 
  
 
 
 DONORS WITHOUT INFECTIONS. 
DONOR  
NAME 
AGE 
  
SEX 
  
BMI 
  
ALCOHOLIC 
  
CO 
MORBIDITIES 
  
DURATION  
OF ICU 
STAY 
NO OF  
INOTROPES 
TC 
  
PLATELETS 
  
T. 
BILIRUBIN 
  
LIVER  
ENZYMES 
BLOOD  
UREA 
S.CREATININE 
  
S. 
NA+ 
  
Karthick 24 M 26.1 YES NO 3 1 4500 123000 0.7 48 45.9 0.8 136.4 
Palanivel 35 M 25.3 YES NO 5 1 7500 160000 0.7 66 47.3 0.8 142.1 
Jayabharathi 23 F 21.6 NO NO 5 1 8600 146000 0.8 42 47.9 0.8 136 
Parthiban     46 M 25.6 NO NO 2 1 14000 150000 1.2 250 52.3 1.2 156 
Kuppan 45 M 24.3 YES NO 2 1 9600 145000 1 70 41 0.9 138 
Perumal   30 M 24.9 NO NO 3 1 7400 12300 1.1 58 47.2 0.8 144 
Prabakaran    29 M 25.7 YES NO 9 1 8900 140000 0.89 100 46.3 0.8 142 
Gaja      50 M 26.8 YES YES 4 2 10000 136000 1 80 36.2 1.1 150 
Mohan       25 M 23.5 NO NO 8 1 6700 120000 0.8 84 42.3 0.45 140 
Annamalai  36 M 25.4 YES NO 2 1 2,700 57,000 0.94 320 61.4 2 152.1 
Sekar                   24 M 23.4 NO NO 2 1 10,600 113000 0.99 280 60.12 1.07 164.3 
Siva doss     19 M 25.4 NO NO 5 1 10,560 12600 0.5 60 45.6 1 150 
Arun  22 M 25.4 NO NO 3 1 12,800 84000 2.1 200 56.2 1.3 146 
Jagan           28 M 26.3 NO NO 3 1 8,900 120000 1.2 55 48.2 0.9 147 
Ram babu          36 M 28 YES NO 3 2 7,700 101000 0.45 48 44.5 0.97 151.7 
srinivasan  23 M 24.1 NO NO 3 1 4,200 64,000 0.54 96 23.69 0.71 146 
arjunan   55 M 23.6 NO YES 2 1 11,600 156000 2.3 190 45.9 1.1 148 
devaraj  60 M 25.7 YES YES 2 1 9,000 100000 0.6 68 45.6 0.4 145 
Kumar 65 M 25.6 NO NO 3 1 2,920 90000 0.5 76 45.3 0.3 147 
       BMI – Body Mass Index, DM – Diabetes Mellitus, MELD – Model for End stage Liver Disease, TC – Total 
Count, S.Na – Serum sodium. 
 
 
 RECIPIENTS WITHOUT DONOR INFECTIONS. 
RECIPIENT 
 NAME  
  
AGE  
  
  
SEX 
  
  
BMI 
  
  
CIRRHOSIS 
  
  
MELD 
  
  
PRE OP EVENTS  
OF 
COMPLICATIONS 
(SBP/HRS/HE) 
DM 
-  
YES/ 
NO 
  
PRE OP  
CULTURE  
STATUS  
COLD 
 
ISCHEMIA  
TIME  
WARM  
ISCHEMIA  
TIME 
POST OP  
CULTURE  
POSITIVITY 
STATUS 
Fathima       42 F 23 YES 15 NO NO NIL 300 80 YES 
Ravichandran  43 M 23 YES 13 YES NO NIL 310 110 NO 
Chandrasekar      51 M 27 YES 15 NO YES NIL 450 90 YES 
Sarathy        35 M 28 YES 16 NO NO NIL 320 70 NO 
Dhanasekar     51 M 26.3 YES 22 NO NO NIL 310 80 NO 
kadanandha              45 M 25.2 NO 17 YES YES insignificant 420 65 YES 
Manickam            59 M 28 YES 12 NO NO NIL 360 70 NO 
Velu 50 M 22.3 YES 16 NO YES NIL 410 90 YES 
Vijayakumar    35 M 25.6 YES 19 NO NO NIL 480 90 YES 
Raju               60 M 25.8 YES 20 NO YES NIL 480 90 YES 
Paranthaman                     55 M 23.1 YES 22 YES NO NIL 390 90 YES 
ponvedha 
muthu  59 M 24.8 YES 17 NO NO NIL 300 120 NO 
valluvamani             48 M 22.1 YES 19 YES NO NIL 450 100 YES 
Rangaraj             40 M 22.7 YES 20 NO NO NIL 320 100 NO 
Damodharan  64 M 23.1 YES 21 NO NO insignificant 450 85 YES 
Velu 61 M 26.3 YES 16 YES YES NIL 315 70 NO 
jayagandhi  40 F 24.9 YES 19 NO YES NIL 300 80 NO 
Balachander   26 M 21.2 YES 24 NO NO NIL 360 90 NO 
Srinivasan 65 M 25.6 YES 25 YES NO  350 100 NO 
   BMI – Body Mass Index, DM – Diabetes Mellitus, MELD – Model for End stage Liver Disease, HE-Hepatic encephalopathy, BP – Spontaneous bacterial 
peritonitis, HRS-Hepato renal syndrome 
COMPARIING RECIPIENTS TO DONORS WITHOUT INFECTIONS: 
DONORS 
  
  
DONOR 
CULTURE  
POSITIVITY 
RECIPIENTS  
  
  
RECIPIENT  
CULTURE  
POSITIVITY 
MORBIDITITY 
  
  
MORTALITY 
  
  
DURATION   
OF 
HOSPITAL 
STAY 
Karthick NO Fathima       YES NO NO 13 
Palanivel NO Ravichandran  NO NO NO 12 
Jayabharathi NO Chandrasekar     YES NO NO 15 
Parthiban     NO Sarathy        NO NO NO 12 
Kuppan NO Dhanasekar     NO NO NO 10 
Perumal   NO kadanandha              YES NO NO 10 
Prabakaran    NO Manickam            NO NO NO 15 
Gaja      NO Velu           YES NO NO 13 
Mohan       NO Vijayakumar    YES NO NO 10 
Annamalai  NO Raju               YES YES YES Mortality 
Sekar                   NO Paranthaman                     YES NO NO 10 
Arun  NO Ponvedamoorthy NO NO NO 11 
Siva doss     NO valluvamani             YES NO NO 12 
Jagan           NO Rangaraj             NO NO NO 13 
Ram babu          NO Damodharan  YES YES NO 18 
srinivasan  NO velu  NO NO NO 10 
arjunan   NO jayagandhi  NO NO NO 13 
devaraj  NO Balchander  NO NO NO 11 
Kumar NO Srinivasan NO NO NO 12 
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